A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis
Published April 4, 2012
Research domains include cellular senescence, circadian regulation, and longevity-focused molecular investigations
A pivotal study published in the New England Journal of Medicine reported that participants who received the highest dose of Zepbound (15 mg) lost an average of 22.5% of their body weight after 72 weeks of treatment
Wu Z, Asokan A, Samulski RJ
Interventions of gut microbiota, obesity and depression Lifestyle modifications, including diet, stress management, exercise, and avoiding harmful substances, are commonly recommended for managing altered gut microbiota, obesity, and depression (Table S1)